Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Seres Therapeutics (MCRB) over the last 6 years, with Q3 2025 value amounting to $351000.0.

  • Seres Therapeutics' Change in Receivables rose 10188.7% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year increase of 10208.22%. This contributed to the annual value of -$8.7 million for FY2024, which is 20000.0% down from last year.
  • Latest data reveals that Seres Therapeutics reported Change in Receivables of $351000.0 as of Q3 2025, which was up 10188.7% from -$18.6 million recorded in Q3 2024.
  • Over the past 5 years, Seres Therapeutics' Change in Receivables peaked at $11.2 million during Q2 2024, and registered a low of -$18.6 million during Q3 2024.
  • Its 4-year average for Change in Receivables is -$821454.5, with a median of -$1.2 million in 2021.
  • In the last 5 years, Seres Therapeutics' Change in Receivables crashed by 296202.53% in 2021 and then surged by 10188.7% in 2025.
  • Seres Therapeutics' Change in Receivables (Quarter) stood at -$1.2 million in 2021, then crashed by 554.64% to -$8.2 million in 2023, then crashed by 127.31% to -$18.6 million in 2024, then skyrocketed by 101.89% to $351000.0 in 2025.
  • Its last three reported values are $351000.0 in Q3 2025, -$18.6 million for Q3 2024, and $11.2 million during Q2 2024.